PMID- 38018208
OWN - NLM
STAT- Publisher
LR  - 20231129
IS  - 1874-4729 (Electronic)
IS  - 1874-4710 (Linking)
DP  - 2023 Nov 24
TI  - Personalized 125I Seed Interstitial Brachytherapy for Patients Aged 80 Years and 
      Over with Early Primary High-risk Non-melanoma Skin Cancer.
LID - 10.2174/0118744710240256231103095018 [doi]
AB  - OBJECTIVE: The aim of this study is to explore the safety and efficacy of 
      iodine-125 seeds interstitial brachytherapy (PISI-BT) for patients aged 80 and 
      above with early primary high-risk non-melanoma skin cancer (NMSC). METHODS: In 
      this retrospective single-center study, we collected and analyzed data from 
      patients >/= 80 years of age with early primary high-risk NMSC treated with PISI-BT 
      between December 2003 and May 2020. Survival status, efficacy, adverse effects 
      (AEs), cosmetic outcomes, and treatment cost were analyzed (data cut-off: 
      November 20th, 2021). RESULTS: Only 9 patients met the inclusion criteria (median 
      age, 86 years (81-90)). Five patients had an Eastern Cooperative Oncology Group 
      (ECOG) score of 1, and allthe patients had at least one comorbidity. Six patients 
      showed complete responseand three showed partial response, while none had stable 
      or progressive disease. No recurrences, disease persistence, or AEs were detected 
      during the follow-up period. After a median follow-up of 29.3 months (3-99), only 
      two patients were alive, but the cause of death in the remaining patients was not 
      related to NMSC. The cosmetic outcomes were excellent and good in two and four 
      patients, respectively, while they could not be evaluated in three patients. The 
      cost (which was within the scope of medical insurance reimbursement) was 
      acceptable. CONCLUSION: PISI-BT could be an alternative treatment option in 
      patients above 80 years old with early primary high-risk NMSC and comorbidities.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Yansong, Liang
AU  - Yansong L
AUID- ORCID: 0000-0003-4212-1495
AD  - Department of Oncology, The Hebei General Hospital, Peace WestRoad348, 050051 
      Shijiazhuang, Hebei Province, China.
FAU - Juan, Wang
AU  - Juan W
AD  - Department of Oncology, The Hebei General Hospital, Peace WestRoad348, 050051 
      Shijiazhuang, Hebei Province, China.
FAU - Hongtao, Zhang
AU  - Hongtao Z
AD  - Department of Oncology, The Hebei General Hospital, Peace WestRoad348, 050051 
      Shijiazhuang, Hebei Province, China.
FAU - Zezhou, Liu
AU  - Zezhou L
AD  - Department of Oncology, The Hebei General Hospital, Peace WestRoad348, 050051 
      Shijiazhuang, Hebei Province, China.
FAU - Xiaohua, Su
AU  - Xiaohua S
AD  - Department of Oncology, The Hebei General Hospital, Peace WestRoad348, 050051 
      Shijiazhuang, Hebei Province, China.
FAU - Huanfen, Zhao
AU  - Huanfen Z
AD  - Department of Pathology, The Hebei General Hospital, Peace West Road 348, 050051 
      Shijiazhuang, Hebei Province, China.
FAU - Rongmei, Zhao
AU  - Rongmei Z
AD  - Department of Interventional Ultrasound, The Hebei General Hospital, Peace 
      WestRoad 348, 050051 Shijiazhuang, Hebei Province, China.
FAU - Jianqi, Yin
AU  - Jianqi Y
AD  - Department of Dermatology, The Hebei General Hospital, Peace West Road348, 050051 
      Shijiazhuang, Hebei Province, China.
LA  - eng
PT  - Journal Article
DEP - 20231124
PL  - United Arab Emirates
TA  - Curr Radiopharm
JT  - Current radiopharmaceuticals
JID - 101468718
SB  - IM
OTO - NOTNLM
OT  - Interstitial brachytherapy
OT  - elderly.
OT  - high-risk
OT  - iodine seeds
OT  - non-melanoma skin cancer
EDAT- 2023/11/29 06:42
MHDA- 2023/11/29 06:42
CRDT- 2023/11/29 03:44
PHST- 2022/12/25 00:00 [received]
PHST- 2023/08/30 00:00 [revised]
PHST- 2023/10/19 00:00 [accepted]
PHST- 2023/11/29 06:42 [medline]
PHST- 2023/11/29 06:42 [pubmed]
PHST- 2023/11/29 03:44 [entrez]
AID - CRP-EPUB-136299 [pii]
AID - 10.2174/0118744710240256231103095018 [doi]
PST - aheadofprint
SO  - Curr Radiopharm. 2023 Nov 24. doi: 10.2174/0118744710240256231103095018.